Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End

Fosrenol will compete directly with Genzyme's Renagel; both products are non-calcium, non-aluminum containing phosphate binders. Shire estimates that less than one-third of the 800,000 ESRD patients with elevated phosphate levels are able to control their phosphorus levels with existing medications.